American Cancer Society prostate cancer survivorship care guidelines

Abstract

https://www.wileyhealthlearning.com/acs.aspx Prostate cancer survivors approach 2.8 million in number and represent 1 in 5 of all cancer survivors in the United States. While guidelines exist for timely treatment and surveillance for recurrent disease, there is limited availability of guidelines that facilitate the provision of posttreatment clinical follow‐up care to address the myriad of long‐term and late effects that survivors may face. Based on recommendations set forth by a National Cancer Survivorship Resource Center expert panel, the American Cancer Society developed clinical follow‐up care guidelines to facilitate the provision of posttreatment care by primary care clinicians. These guidelines were developed using a combined approach of evidence synthesis and expert consensus. Existing guidelines for health promotion, surveillance, and screening for second primary cancers were referenced when available. To promote comprehensive follow‐up care and optimal health and quality of life for the posttreatment survivor, the guidelines address health promotion, surveillance for prostate cancer recurrence, screening for second primary cancers, long‐term and late effects assessment and management, psychosocial issues, and care coordination among the oncology team, primary care clinicians, and nononcology specialists. A key challenge to the development of these guidelines was the limited availability of published evidence for management of prostate cancer survivors after treatment. Much of the evidence relies on studies with small sample sizes and retrospective analyses of facility‐specific and population databases. CA Cancer J Clin 2014;64:225–249. © 2014 American Cancer Society.

Enhancing Survivorship Care Planning for Patients With Localized Prostate Cancer Using a Couple-Focused mHealth Symptom Self-Management Program: Protocol for a Feasibility Study (Preprint)

“…[26][27][28][29] The substantial travel, time, and expense required to participate in in-person, multi-session, couple-focused supportive care programs limit the accessibility of these programs for patients and partners. Scalable interventions are needed to address the gap in survivorship care planning.…”

“…The eligible patients must (1) be within 16 weeks of completing their initial treatment with curative intent for localized prostate cancer (i.e., prostatectomy or radiotherapy +/-hormonal treatment) [36] at the genitourinary and radiation oncology clinics of the two Comprehensive Cancer Centers in the southeast of U.S.; (2) not be receiving treatment currently or within the past year for another cancer; and (3) have a partner who is 18 years of age or older, not receiving cancer treatment currently or within the past year, and willing to participate. [29] Patients and their partners will be removed from this study if she or he is diagnosed with a new type of cancer, starts new treatment for another cancer during the study period, or decides to withdraw from the study voluntarily. Patients and their partners will be excluded from the study if either partner does not read and speak English as evidenced by their understanding and responses to screening questions and self-reported ability to read English, or has cognitive impairment (assessed by the Short Portable Mental Status Questionnaire).…”

“…[24,25] Management of these negative effects has been an unaddressed supportive care need for survivors and their partners. [26][27][28] The IOM [3] and American Cancer Society (ACS) [29] cancer care guidelines call for programs that address treatment-related effects, promote healthy behaviors, and maintain quality of life for patients and their families.…”

Functional Role of WT1 in Prostate Cancer

“…Ninety-nine percent of patients who develop primary PC are expected to live at least 5 years after diagnosis (52). Ninety-eight percent are alive after 10 years, and 94% live for at least 15 years if the disease remains localized.…”

“…Ninety-eight percent are alive after 10 years, and 94% live for at least 15 years if the disease remains localized. By contrast, patients with metastatic disease at diagnosis have a 5-year survival rate of only 28% (52). The process of metastasis requires that cancer cells acquire characteristics of enhanced motility and invasiveness.…”